Evidence map›Paper›PMID 42667498›Full record

ReviewMolecular biology reports2026

miR-142-3p in cancer: intracellular tumor suppression and extracellular vesicle- mediated microenvironmental signaling.

Michelle van der Merwe, Rebecca Towle, Kathy Myburgh, Cathie Garnis, Anna-Mart Engelbrecht

Abstract readReview
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michelle van der MerweDepartment of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa. mvdmerwe@bccrc.ca.
Rebecca TowleDepartment of Basic and Translational Research, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
Kathy MyburghDepartment of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa.
Cathie GarnisDepartment of Basic and Translational Research, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
Anna-Mart EngelbrechtDepartment of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR-142-3p has emerged as an important regulator of cancer progression and treatment response, exhibiting predominantly tumor-suppressive functions. Intracellularly, miR-142-3p inhibits proliferation, promotes apoptosis, suppresses epithelial-mesenchymal transition (EMT), and enhances chemosensitivity through the downregulation of key pathways, including HMGB1, Wnt/β-catenin, and SIRT1-mediated autophagy. Notably, miR-142-3p is frequently enriched in extracellular vesicles (EVs), indicating selective export from tumor cells. This EV-mediated trafficking introduces functional complexity, as the loss of intracellular miR-142-3p may attenuate its tumor-suppressive effects, while its transfer to recipient cells within the tumor microenvironment (TME) may exert context-dependent roles. Within the TME, miR-142-3p has been associated with the regulation of cancer-associated fibroblast (CAF) activation, angiogenesis, and immune responses. Emerging evidence further suggests a potential role for EV-associated miR-142-3p in systemic processes such as cancer-associated cachexia through modulation of muscle-related pathways, although this remains poorly defined. This review summarizes the dual intracellular and extracellular functions of miR-142-3p in cancer and highlights its contribution to treatment sensitivity and TME interactions. We also discuss current challenges and future directions, including therapeutic strategies aimed at restoring intracellular miR-142-3p levels or modulating its EV-mediated transfer. A deeper understanding of its context-dependent roles will be critical for the development of targeted and clinically relevant therapeutic approaches.

Indexed as

Extracellular VesiclesMicroRNAsNeoplasmsTumor MicroenvironmentAnimalsApoptosisEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansSignal TransductionMicroRNAsMIR142, humanCancerExtracellular vesiclesmiR-142-3pmiRNATreatment resistanceTumor microenvironment

Identifiers

PMID42667498
PMCPMC13526142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.